Organization and Functions of the Administrative Core (CAdmin). As a Principal Investigator of the proposed TCCN, Dr. Mauro Ferrari is Chairman of the Department of Nanomedicine and Biomedical Engineering (nBME). Dr. Ferrari holds concurrent faculty appointments at MDACC (tenured Full Professor, Experimental Therapeutics), Rice University (Bioengineering) and UT Austin (Biomedical Engineering), and is the President of the Alliance for NanoHealth (ANH). Dr. Ferrari is trained in mathematics, mechanical engineering and medicine. He is a recognized leader in the development and applicafion of biomedical nanotechnology. Among many awards he received. Dr. Ferrari is the recipient of the DoD CDMRP Breast Cancer Research Program's Innovator Award in 2008. Co-leading the TCCN as Principal Invesfigator is Dr. Anil K. Sood of MDACC, Professor and Director ofthe Blanton-Davis Ovarian Cancer Research Program in the Departments of Gynecologic Oncology and Cancer Biology. He is also the Director of the Center for RNA Interference and Non-Coding RNA at MDACC. Dr. Sood is a renowned physician scienfist known for his research on the systemic in vivo siRNA delivery using biocompafible nanoparticles and development of novel anti-vascular therapeufic approaches. Dr. Gabriel Lopez-Berestein Is the third Principal Investigator, and is currently Professor of Medicine and Cancer Biology, Department of Experimental Therapeutics, Division of Cancer Medicine, MDACC;Executive Director, PDC at MDACC and Adjunct Professor at Rice University (Bioengineering). Dr. Lopez-Berestein is a widely recognized expert in the field of liposomal therapeufics and in translafional research. TCCN Administrative Core will be advised by Dr. Raymond DuBois, Other Significant Contributor of TCCN and Provost/Executive Vice President of MDACC. Drs. Ferrari, Sood, and Lopez-Berestein will lead the TCCN from the perspecfives of applied nanotechnology, clinical oncology, and translational work for pharmaceutical development, respectively. Each of them has demonstrated experience to conduct and lead mulfidisciplinary research programs that bridge the physical sciences and biomedical and clinical sciences. The CAdmin led by the Pis will be assisted by a Center Manager, Dr. Jason Sakamoto, to provide leadership and general administration for all activities related to this TCCN. In particular, CAdmin is responsible for: 1) providing administrafive support to all projects and core resources of the TCCN, 2) providing administrative support to develop and manage pilot project programs (Internal pilot projects and Trans-Alliance challenge projects), 3) convening TCCN team meetings, advisory committee meetings, as well as scientific conferences and workshops, 4) supporting the participation of the TCCN in the NCI Alliance for Nanotechnology in Cancer and communicate with NCI staff, facilitate and prepare the TCCN participation in NCI evaluafion, 5) facilitafing communication with other CCNE programs, and among other administrafive and supportive funcfions, and 6) interfacing with other administrative resources (ANH and nBME) and shared core facilities in the participating institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151668-04
Application #
8549996
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
4
Fiscal Year
2013
Total Cost
$362,330
Indirect Cost
$25,560
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Seo, Hyeonglim; Choi, Ikjang; Whiting, Nicholas et al. (2018) Hyperpolarized Porous Silicon Nanoparticles: Potential Theragnostic Material for 29 Si Magnetic Resonance Imaging. Chemphyschem 19:2143-2147
Koay, Eugene J; Lee, Yeonju; Cristini, Vittorio et al. (2018) A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 24:5883-5894
Zacharias, Niki; Lee, Jaehyuk; Ramachandran, Sumankalai et al. (2018) Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. Mol Imaging Biol :
Hövener, Jan-Bernd; Pravdivtsev, Andrey N; Kidd, Bryce et al. (2018) Parahydrogen-Based Hyperpolarization for Biomedicine. Angew Chem Int Ed Engl 57:11140-11162
Mai, Junhua; Li, Xin; Zhang, Guodong et al. (2018) DNA Thioaptamer with Homing Specificity to Lymphoma Bone Marrow Involvement. Mol Pharm 15:1814-1825
Kojic, M; Milosevic, M; Kojic, N et al. (2018) Mass release curves as the constitutive curves for modeling diffusive transport within biological tissue. Comput Biol Med 92:156-167
Khalid, Ayesha; Persano, Stefano; Shen, Haifa et al. (2017) Strategies for improving drug delivery: nanocarriers and microenvironmental priming. Expert Opin Drug Deliv 14:865-877
Venuta, Alessandro; Wolfram, Joy; Shen, Haifa et al. (2017) Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B 5:207-219
Kanlikilicer, Pinar; Ozpolat, Bulent; Aslan, Burcu et al. (2017) Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids 9:251-262
Rodriguez-Aguayo, Cristian; Monroig, Paloma Del C; Redis, Roxana S et al. (2017) Regulation of hnRNPA1 by microRNAs controls the miR-18a-K-RAS axis in chemotherapy-resistant ovarian cancer. Cell Discov 3:17029

Showing the most recent 10 out of 332 publications